KISSEI PHARMACEUTICAL CO.,LTD. (4547.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	97.4B	97.4B	88.3B	75.6B	67.5B
Cost of Revenue	11.1B	51.6B	44.3B	38.2B	35.1B
Gross Profit	11.1B	45.8B	44.1B	37.3B	32.4B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	9.0B	48.7B	38.3B	33.3B	33.5B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	9.0B	48.7B	38.3B	33.3B	33.5B
Cost and Expenses	100.3B	100.3B	82.6B	71.6B	68.6B
Operating Income (EBIT)	(2.9B)	(2.9B)	5.8B	4.0B	(1.1B)
Non-Operating
Interest Income	25.0M	148.0M	57.0M	21.0M	23.0M
Interest Expense	6.0M	28.0M	21.0M	18.0M	20.0M
Net Interest Income	19.0M	120.0M	36.0M	3.0M	3.0M
Other Non-Op Income/Expense	807.0M	1.8B	1.2B	2.1B	1.7B
Non-Operating Income (excl Interest)	814.0M	2.1B	1.5B	2.3B	1.8B
EBT (Pre-Tax Income)	5.7B	16.9B	15.6B	14.4B	13.7B
Income Tax Expense	1.2B	2.9B	3.6B	3.2B	3.0B
Bottom Line
Net Income	13.8B	13.8B	12.0B	11.2B	10.5B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	13.8B	13.8B	12.0B	11.2B	10.5B
Per Share
Basic EPS	¥330	¥332	¥274	¥247	¥228
Diluted EPS	¥330	¥332	—	—	—
Revenue Per Share	¥2,344	¥2,344	¥2,025	¥1,670	¥1,464
Shares
Basic Shares Outstanding	41.6M	41.6M	43.6M	45.3M	46.1M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	1.7B	10.4B	8.3B	3.0B
D&A	—	4.6B	4.6B	4.3B	4.1B
EBIT	(2.9B)	(2.9B)	5.8B	4.0B	(1.1B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026